Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $40.1538.

Several equities research analysts have issued reports on JANX shares. Wedbush decreased their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Guggenheim decreased their target price on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, May 8th. UBS Group downgraded shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.00 to $15.00 in a research note on Wednesday, April 15th. Finally, Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their target price for the company from $29.00 to $14.00 in a research note on Monday, April 20th.

Janux Therapeutics Stock Up 0.3%

JANX opened at $15.36 on Wednesday. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The company has a 50 day moving average of $14.37 and a two-hundred day moving average of $14.12. The company has a market cap of $936.65 million, a P/E ratio of -8.35 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. Research analysts anticipate that Janux Therapeutics will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the transaction, the vice president directly owned 32,270 shares in the company, valued at approximately $457,265.90. This represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in shares of Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the period. Nuveen LLC raised its holdings in Janux Therapeutics by 0.8% in the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock valued at $1,331,000 after acquiring an additional 787 shares in the last quarter. Congress Asset Management Co. raised its holdings in Janux Therapeutics by 2.8% in the fourth quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock valued at $791,000 after acquiring an additional 1,569 shares in the last quarter. ProShare Advisors LLC raised its holdings in Janux Therapeutics by 18.3% in the fourth quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after acquiring an additional 1,621 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in Janux Therapeutics by 7.6% in the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after acquiring an additional 1,846 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.